Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00754624 · ClinicalTrials.gov registry record · Phase 2
An Open-label, Multi-center, International, Three-year, Safety and Tolerability 'Follow on' Trial
A Phase 2 study of Type 2 Diabetes Mellitus, sponsored by Mannkind Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 229
- Enrollment target
- 20
- Study locations
NCT00754624 is a Phase 2 study of Type 2 Diabetes Mellitus that has completed, run by Mannkind Corporation. The registered enrollment target is 229 participants, below the 2,747-participant average among 122 other Type 2 Diabetes Mellitus trials with a reported enrollment target (92% lower). The trial reports 20 study locations across 11 states.
The verdict
NCT00754624, a Phase 2 study of Type 2 Diabetes Mellitus, has completed, sponsored by Mannkind Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 229 participants
- Enrollment target
- 20
- Study locations
Study Summary
Safety Follow-Up Trial to PDC-INS-0008 and MKC-TI-005
Conditions Studied
Interventions
- DRUG Technosphere® Insulin Inhalation Powder and MedTone™ Inhaler
Study Locations (20)
Texas
- Dallas Diabetes & Endocrine Center - Dallas
- University of Texas Southwestern Medical Center - Dallas
- Texas Diabetes Institute - San Antonio
- Diabetes & Glandular Disease Research Assoc PA - San Antonio
Connecticut
- Alliance Medical Group of Greater Waterbury - Middlebury
- The Hospital of Central Connecticut - New Britain
- Soundview Research Associates - Norwalk
BGR
- MBAL "Pleven" - Pleven
- SBALENG-Sofia Institute of Endocrinology - Sofia
- MBAL Alexandrovska Hospital - Sofia
California
- Dorothy L & James E Frank Diabetes Research Institute - San Mateo
- Sansum Medical Research Institute - Santa Barbara
New York
- Diabetes Care & Information Center of New York - Flushing
- Diabetes Team Associated - New York
Florida
- University of Miami School of Medicine - Miami
Louisiana
- Oschner Clinic Foundation - New Orleans
Minnesota
- International Diabetes Center - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 229 participants |
| Start Date | 2004-05 |
| Est. Completion | 2008-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00754624
The ClinicalTrials.gov registry entry for NCT00754624 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 229 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,747-participant average among 122 other Type 2 Diabetes Mellitus trials with a reported enrollment target (92% lower). The listed sponsor is Mannkind Corporation, which has 42 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Type 2 Diabetes Mellitus appearing as the primary indexed condition, and to 1 intervention - of which Technosphere® Insulin Inhalation Powder and MedTone™ Inhaler is the first listed.
NCT00754624 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Texas, Connecticut, BGR.
Frequently Asked Questions
What is clinical trial NCT00754624 about?
NCT00754624 is a clinical study titled "An Open-label, Multi-center, International, Three-year, Safety and Tolerability 'Follow on' Trial". Safety Follow-Up Trial to PDC-INS-0008 and MKC-TI-005
What is the current status of trial NCT00754624?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 229 participants. The study started on 2004-05. Estimated completion is 2008-10.
What conditions does trial NCT00754624 study?
This clinical trial studies the following conditions: Type 2 Diabetes Mellitus.
What interventions are being tested in trial NCT00754624?
The interventions under investigation include: Technosphere® Insulin Inhalation Powder and MedTone™ Inhaler (DRUG).
Who is sponsoring clinical trial NCT00754624?
This trial is sponsored by Mannkind Corporation, which has 42 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00754624 being conducted?
This trial has 20 study locations across California, Connecticut, Florida, Louisiana, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 Diabetes
RECRUITING · Phase 2
-
Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease
RECRUITING · Phase 2
-
Regulation of Endogenous Glucose Production by Central KATP Channels
RECRUITING · Phase 2
-
Signaling Mechanisms and Vascular Function in Patients With Diabetes Mellitus
COMPLETED · Phase 2
-
The Effect of Bariatric Surgery on Metabolism, the Metabolome and Microbiome in Patients With Type 2 Diabetes
COMPLETED · Phase 2
-
A Study to Evaluate Safety and Efficacy of TTP054 for 12 Weeks in Subjects With Type 2 Diabetes
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.